Home>Topics>Companies>Ranbaxy Laboratories

Ranbaxy Laboratories

  1. All
  2. Commentary
  3. Headlines
  1. UPDATE 1-U.S. court denies Ranbaxy's bid to block launch of rival generics

    Headlines

    Thu, 20 Nov 2014

    (Adds Endo's launch of generic Valcyte and Dr. Reddy's comment)

  2. U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs

    Headlines

    Thu, 20 Nov 2014

    Nov 20 (Reuters) - A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.

  3. UPDATE 1- Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

    Headlines

    Tue, 18 Nov 2014

    * Ranbaxy alleges FDA's move violated constitutional rights

  4. Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

    Headlines

    Tue, 18 Nov 2014

    MUMBAI, Nov 18 (Reuters) - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium, court documents showed.

  5. Sun's Gross Profit Expands Driven by U.S. Subsidiary Price Increases; Shares Fairly Priced

    Commentary

    Sun, 16 Nov 2014

    Quarterly revenue for the yet-to-merge Ranbaxy business was up 16% and profit turned ..... prior period and accounted for 44% of Ranbaxy 's quarterly sales). We believe ..... further enhanced with the addition of Ranbaxy to its portfolio.

  6. Upgrading Sun's Fair Value as we Include Ranbaxy in our Forecast; Narrow Moat Remains Intact

    Commentary

    Sun, 9 Nov 2014

    largely the result of incorporating Ranbaxy financials into our forecast starting 1 April 2014. We believe the Ranbaxy acquisition will strengthen Sun ..... to expand the operating margins of Ranbaxy post-merger. These include manufacturing

  7. India's Ranbaxy shares fall; U.S FDA revokes approval for some drugs

    Headlines

    Thu, 6 Nov 2014

    MUMBAI, Nov 7 (Reuters) - India's Ranbaxy Laboratories Ltd fell 4.4 percent in pre-open trading on Friday after the U.S. Food and Drug Administration (FDA) revoked tentative approval for certain generic drugs.

  8. UPDATE 2-U.S. pulls approval for Ranbaxy copies of AstraZeneca and Roche drugs

    Headlines

    Thu, 6 Nov 2014

    * Ranbaxy says FDA revoked approval for copies of Nexium, Valcyte

  9. UPDATE 1-US pulls approval for Ranbaxy copies of AstraZeneca, Roche drugs

    Headlines

    Thu, 6 Nov 2014

    * Ranbaxy says FDA revoked approval for copies of Nexium, Valcyte

  10. BRIEF-AstraZeneca CEO says not sure how to read Ranbaxy announcement on Nexium

    Headlines

    Thu, 6 Nov 2014

    Nov 6 (Reuters) - AstraZeneca CEO and CFO, in call with analysts: * CEO says "not totally sure" how to read Ranbaxy announcement on generic

« Prev12345Next »
Content Partners